Seborrheic Dermatitis

  • Andrea Kovacikova CurkovaEmail author
  • Maria Simaljakova


Seborrheic dermatitis is a common chronic relapsing inflammatory skin disorder that varies in severity between individuals and with time. Although the exact cause of this disease is not well understood, there is increasing understanding of the etiopathogenesis. Seborrheic dermatitis is a multifactorial disease. Both endogenous and exogenous predisposing factors are involved in its development. Presence of these factors leads to reproduction of the saprophytic opportunistic pathogen Malassezia spp. The inflammatory reaction against Malassezia yeast is considered basic in the etiology. The mechanisms via which these yeasts cause inflammation remain controversial. The current therapeutic approach is based on the wide range of topical antifungal formulations, keratolytics, and anti-inflammatory and immunomodulatory agents, which provide safe, effective, and flexible treatment options for seborrheic dermatitis. Significant improvement can also be achieved by systemic antifungals and phototherapy. It should be kept in mind that severe and therapy-resistant forms of seborrheic dermatitis can be a predictor of some serious conditions such as HIV infection.


Seborrheic dermatitis Malassezia yeast Antifungal treatment Calcineurin inhibitors Corticosteroids Zinc pyrithione Metronidazole Lithium salts Phototherapy 

Further Reading

  1. Barzilai A, David M, Trau H, Hodak E. Seborrheic dermatitis-like eruption in patients taking isotretinoin therapy for acne: retrospective study of five patients. Am J Clin Dermatol. 2008;9:255–61.CrossRefGoogle Scholar
  2. Berk T, Scheinfeld N. Seborrheic dermatitis. Pharm Ther. 2010;35(6):348–52.Google Scholar
  3. Bieber T. Other types of dermatitis. In: Burgdorf WHC, Plewig G, Wolff HH, Landthaler M, editors. Braun Falco’s dermatology. Heidelberg: Springer; 2009. p. 425–33.CrossRefGoogle Scholar
  4. Bukvic Mokos Z, Kralj M, Basta-Juzbasic A, Lakos Jukic I. Seborrheic dermatitis: an update. Acta Dermatovenerol Croat. 2012;20(2):98–104.PubMedGoogle Scholar
  5. Danby FW, Maddin WS, Margesson LJ, Rosenthal D. A randomized, double blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol. 1993;29:1008–12.CrossRefGoogle Scholar
  6. Dreno B, Moyse D. Lithium gluconate in the treatment of seborrhoeic dermatitis: a multicenter, randomized, double blind study versus placebo. Eur J Dermatol. 2002;12:549–52.PubMedGoogle Scholar
  7. Gaitanis G, Velegraki A, Alexopoulos EC, Chasapi V, Tsigonia A, Katsambas A. Distribution of Malassezia species in pityriasis versicolor and seborrhoeic dermatitis in Greece. Typing of the major pityriasis versicolor isolate M. globosa. Br J Dermatol. 2006;154:854–9.CrossRefGoogle Scholar
  8. Geissler SE, Michelsen S, Plewig G. Very low dose isotretinoin is effective in controlling seborrhea. J Dtsch Dermatol Ges. 2003;1:952–8.CrossRefGoogle Scholar
  9. Ianosi S, Stoicescu I, Ianosi G, Neagoe D, Georgescu CV. The study of CD20 and CD45.Ro antibodies in the inflammatory infiltrate involved in acne and seborrheic dermatitis. Rom J Morphol Embryol. 2007;48:285–9.PubMedGoogle Scholar
  10. Kalinowska-Pujdak A, Schmalreck A, Haustein UF, Nenoff P. Species differentiation of the genus Malassezia with Fourier transform infrared spectroscopy. Hautarzt. 2006;57:127–36.CrossRefGoogle Scholar
  11. Koca R, Altinyazar HC, Esturk E. Is topical metronidazole effective in seborrhoeic dermatitis? A double-blind study. Int J Dermatol. 2003;42:632–5.CrossRefGoogle Scholar
  12. Naldi L, Rebora A. Seborrheic dermatitis. N Engl J Med. 2009;360:387–96.CrossRefGoogle Scholar
  13. Nnoruka EN, Chukwuka JC, Anisuiba B. Correlation of mucocutaneous manifestations of HIV/AIDS infection with CD4 counts and disease progression. Int J Dermatol. 2007;46 Suppl 2:14–8.CrossRefGoogle Scholar
  14. Piérard GE, Ausma J, Henry F, Vroome V, Wouters L, Borgers M, et al. A pilot study on seborrheic dermatitis using pramiconazole as a potent oral anti-Malassezia agent. Dermatology. 2007;214:162–9.CrossRefGoogle Scholar
  15. Pierard-Franchimont C, Goffin V, Decroix J, Pierard GE. A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrhoeic dermatitis. Skin Pharmacol Appl Skin Physiol. 2002;15:434–41.CrossRefGoogle Scholar
  16. Ratnavel RC, Squire RA, Boorman GC. Clinical efficacies of shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrhoeic dermatitis. J Dermatol Treat. 2007;18:88–96.CrossRefGoogle Scholar
  17. Sampaio AL, Mameri AC, Vargas TJ. Seborrheic dermatitis. An Bras Dermatol. 2011;86(6):1061–71.CrossRefGoogle Scholar
  18. Schwartz JR, Messenger AG, Tosti A, Todd G, Hordinsky M, Hay RJ, et al. A comprehensive pathophysiology of dandruff and seborrheic dermatitis – towards a more precise definition of scalp health. Acta Derm Venereol. 2013;93:131–7.CrossRefGoogle Scholar
  19. Shin H, Kwon OS, Won CH, Kim BJ, Lee YW, Choe YB, et al. Clinical efficacies of topical agents for the treatment of seborrhoeic dermatitis of the scalp: a comparative study. J Dermatol. 2009;36(3):131–7.CrossRefGoogle Scholar
  20. Stefanaki I, Katsambas A. Therapeutic update on seborrheic dermatitis. Skin Ther Lett. 2010;15:1–4.Google Scholar
  21. Tajima M, Sugita T, Nishikawa A, Tsuboi R. Molecular analysis of Malassezia microflora in seborrheic dermatitis patients: comparison with other diseases and healthy subjects. J Invest Dermatol. 2008;128:345–51.CrossRefGoogle Scholar
  22. Tsuji K, Nose Y, Ito M, Ozala A, Matsuo I. HLA antigens and susceptibility to psoriasis vulgaris in a non-Caucasian population. Tissue Antigens. 1976;8:29–33.CrossRefGoogle Scholar
  23. Warshaw EM, Wohlhuter RJ, Liu A, Zeller SA, Wenner RA, Bowers S, et al. Results of a double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1 % for the treatment of moderate to severe facial seborrhoeic dermatitis. J Am Acad Dermatol. 2007;57:257–64.CrossRefGoogle Scholar
  24. Watanabe S, Kano R, Sato H, Nakamura Y, Hasegawa A. The effects of Malassezia yeasts on cytokine production by human keratinocytes. J Invest Dermatol. 2001;116:769–73.CrossRefGoogle Scholar
  25. Zisova LG. Malassezia species and seborrheic dermatitis. Folia Med (Plovdiv). 2009;51(1):23–33.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Dermatology and VenereologyComenius University Faculty of MedicineBratislavaSlovakia

Personalised recommendations